Delveinsight

AUGUST 4, 2020

MorphoSys in-licensed Monjuvi, which is a humanized Fc-engineered monoclonal antibody against CD19 – the same protein which CAR-T cell therapies target and is in abundance in cancerous B cells, from Xencor in 2010 and is under evaluation in B-cell malignancies in several ongoing combination trials.

Cardiology 55

Cardiology Antibody FDA Approval Trials 55

pharmaphorum

DECEMBER 21, 2020

A first-in-class treatment discovered by Alnylam and then licensed to The Medicines Company, the drug is being developed for treatment for hyperlipidaemia in adults who have elevated low-density lipoprotein cholesterol (LDL-C) while being on a maximum tolerated dose of a statin therapy. billion late last year.

Drugs 52

Drugs RNA Manufacturing Licensing 52

The Pharma Data

AUGUST 30, 2021

Results were presented at the ESC Congress 2021, organized by the European Society of Cardiology (ESC). Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.

RNA 52

RNA Trials Production Containment 52

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33 Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

DECEMBER 12, 2020

It plays a crucial role in many inflammatory and autoimmune diseases across multiple therapy areas, including haematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. 1 The global rare disease market is forecasted to grow by a low double digit percentage in the future.

Development 75

Development Regulation Medicine Containment 75

The Pharma Data

AUGUST 29, 2020

Presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology, the analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran) from the Phase III trials.

Medicine 52

Medicine Containment Trials Production 52

The Pharma Data

APRIL 26, 2021

billion declined, mainly due to the USD 650 million upfront payment to in-license tislelizumab from BeiGene. This decline was mainly due to the USD 650 million upfront payment to in-license tislelizumab from BeiGene and lower operating income adjusted for non-cash items, partly offset by favorable changes in working capital.

Sales 40

Sales Medicine Production Manufacturing 40

The Pharma Data

NOVEMBER 4, 2020

Amarin’s decision to continue to invest in expanding the market for VASCEPA also reflects its confidence in its manufacturing processes, which the company has built over a decade to achieve consistent, high-quality, stable supply to support anticipated global demand. This compares with licensing and royalty revenue of $0.2

Sales 40

Sales Production Marketing Cardiology 40

The Pharma Data

SEPTEMBER 15, 2020

The results demonstrated that Penta immune responses were robust and noninferior to licensed meningococcal vaccines (MenB and MenACWY) in individuals 10-25 years of age, regardless of prior MenACWY exposure. A Phase 2 proof-of-concept study of Pfizer’s potential first-in-class pentavalent meningococcal vaccine candidate (Penta; MenABCWY).

Vaccine 52

Vaccine Vaccination Gene Therapy Trials 52

The Pharma Data

OCTOBER 29, 2020

Established ULTOMIRIS as new standard of care in PNH ahead of set goal, with more than 70% patient conversion from SOLIRIS ® (eculizumab) in 3 largest markets – U.S. ALXN2060 (AG10) – Eidos: Alexion holds an exclusive license to develop and commercialize ALXN2060 (AG10) in Japan. Received U.S. Germany & Japan.

Sales 40

Sales Clinical Trials Clinical Trials Production 40

Cloudbyz

AUGUST 16, 2024

By automating many of the processes that were once manual and error-prone, eCRFs allow research teams to focus on what truly matters: advancing scientific knowledge and bringing new treatments to market more efficiently. How does Cloudbyz eCRF stand out in the market? Can eCRFs be adapted for post-market surveillance studies?

Clinical Trials 52

Clinical Trials Clinical Trials Compliance Trials 52

The Pharma Data

APRIL 1, 2021

. “When our specialties collaborate, we give our patients the best chance of success – which is highlighted in our professional society guidelines, including those from the American Diabetes Association and the American College of Cardiology.” Diabetes/CV Marketing, Lilly Diabetes. ” About the Survey.

Nurses 52

Nurses Cardiology Medicine Insulin 52

XTalks

DECEMBER 19, 2024

The agency issued a complete response letter (CRL) for the biologics license application (BLA) for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration. percent, including impacts from its 2023 acquisition of cardiology medtech company Laminar.

Sales 97

Sales FDA Approval Licensing Licensing 97